The PASPORT clinical trial research program will evaluate pasireotide for the treatment of a range of neuroendocrine tumors.
Key Inclusion Criteria:
At least 18 years of age with histologically confirmed, well-differentiated unresectable or metastatic neuroendocrine carcinoma of the lung or thymus
At least one measurable lesion defined by RECIST 1.1 criteria
Radiological confirmation of disease progression within the last 12 months
WHO performance status of 0,1, or 2
Key Exclusion Criteria:
Poorly differentiated neuroendocrine carcinoma, non-neuroendocrine thymoma, and mixed tumors
Prior treatment with
Any long-acting somatostatin analogue within the last 2 months
Radioligand therapy within the last 6 months
Chemotherapy, immunotherapy, or radiotherapy within the last 3 months
Known intolerance or hypersensitivity to pasireotide, octreotide, or other SST analogues and everolimus, or other rapamycin analogues
Abbreviations: LAR=long-acting release; mTOR=mammalian target of rapamycin; NETs=neuroendocrine tumors; RECIST=Response Evaluation Criteria in Solid Tumors; SST=somatostatin receptor subtype; WHO=World Health Organization
Disclaimer: This is a global web site for Pasport™ providing general information for healthcare professionals from all countries. The information on this site is not country-specific and may contain program information that is different from where you practice. Please contact your local Novartis representative for the latest information specific to your country.